UPDATE 1-Resverlogix halts trial to modify enrollment process

* Trial testing drug to treat thickening of artery walls

* Says completes dosing in drug's other mid-stage trial

* Shares fall 7 pct

May 12 (Reuters) - Canadian biotechnology company Resverlogix Corp (RVX.TO) said it temporarily halted a mid-stage trial of its experimental drug to treat thickening of arterial walls, to modify its enrollment procedure, sending its shares down as much as 7 percent.

"We believe that we can enhance the enrollment procedure by modifying the inclusion criteria," Chief Executive Donald McCaffrey said in a statement.

The drug RVX-208 is being studied to treat atherosclerosis, a disease where plaque builds up inside the arteries, which could lead to a heart attack.

Currently, the criteria for the Assure trial requires the patient to have had a heart attack within the past four weeks. The patient is then required to voluntarily submit to having two invasive intravascular ultrasound both at the start and finish of the 90 day drug treatment period.

The company also said it completed the dosing of the drug's other mid-stage trial, Assert, five months ahead of schedule without any alterations to the dose levels of the three drug receiving cohorts.

"Since the Assert trial provides us with data much faster than first anticipated, we can also now apply pertinent findings to the Assure trial," McCaffrey said.

Shares of the company were down 6 percent at C$5.95 during afternoon trade on the Toronto Stock Exchange. They touched a low of C$5.89 earlier in the session. (Reporting by Isheeta Sanghi in Bangalore; Editing by Aradhana Aravindan) ((isheeta.sanghi@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: isheeta.sanghi.thomsonreuters.com@reuters.net))